DNA repair of myeloma plasma cells correlates with clinical outcome: The effect of the nonhomologous end-joining inhibitor SCR7


Gkotzamanidou M, Terpos E, Bamia C, Munshi NC, Dimopoulos MA, Souliotis VL. DNA repair of myeloma plasma cells correlates with clinical outcome: The effect of the nonhomologous end-joining inhibitor SCR7. Blood [Internet]. 2016;128(9):1214 - 1225.


DNA repair activity of malignant cells seems to influence therapeutic outcome and patients' survival. Herein, we investigated the mechanistic basis for the link between DNA repair efficiency and response to antimyeloma therapy. Nucleotide excision repair (NER), interstrand cross-links repair (ICL/R), double-strand breaks repair (DSB/R), and chromatin structure were evaluated in multiple myeloma (MM) cell lines (melphalan-sensitive RPMI8226; melphalan-resistant LR5) and bone marrow plasma cells (BMPCs) from MM patients who responded (n = 17) or did not respond (n = 9) to subsequent melphalan therapy. The effect of DSB/R inhibition was also evaluated. Responders' BMPCs showed slower rates of NER and DSB/R (P < .0022), similar rates of ICL/R, and more condensed chromatin structure compared with nonresponders. Moreover, apoptosis rates of BMPCs were inversely correlated with individual DNA repair efficiency and were higher in responders' cells compared with those of nonresponders (P = .0011). Similarly, RPMI8226 cells showed slower rates of NER and DSB/R, comparable rates of ICL/R, more condensed chromatin structure, and higher sensitivity than LR5 cells. Interestingly, cotreatment of BMPCs or cell lines with DSB/R inhibitors significantly reduced the rates ofDSB/R and increasedmelphalan sensitivity of the cells, with the nonhomologous end-joining inhibitor SCR7 showing the strongest effect. Together, responders' BMPCs are characterized by lower efficiencies of NER and DSB/R mechanisms, resulting in higher accumulation of the extremely cytotoxic ICLs andDSBs lesions,which in turn triggers the induction of the apoptotic pathway. Moreover, the enhancement of melphalan cytotoxicity by DSB/R inhibition offers a promising strategy toward improvement of existing antimyeloma regimens. © 2016 by The American Society of Hematology.


Export Date: 18 February 2017References: Chng, W.J., Glebov, O., Bergsagel, P.L., Kuehl, W.M., Genetic events in the pathogenesis of multiple myeloma (2007) Best Pract Res Clin Haematol, 20 (4), pp. 571-596;Anderson, K.C., Carrasco, R.D., Pathogenesis of myeloma (2011) Annu Rev Pathol, 6, pp. 249-274; Giralt, S., 200 mg/m2 melphalan-The gold standard for multiple myeloma (2010) Nat Rev Clin Oncol, 7 (9), pp. 490-491; Cavo, M., Rajkumar, S.V., Palumbo, A., International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation (2011) Blood, 117 (23), pp. 6063-6073; San Miguel, J.F., Schlag, R., Khuageva, N.K., Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma (2008) N Engl J Med, 359 (9), pp. 906-917; Redic, K., Carfilzomib: A novel agent for multiple myeloma (2013) J Pharm Pharmacol, 65 (8), pp. 1095-1106; Anderson, K.C., The 39th David A. Karnofsky Lecture: Bench-to-bedside translation of targeted therapies in multiple myeloma (2012) J Clin Oncol, 30 (4), pp. 445-452; Kumar, S.K., Lee, J.H., Lahuerta, J.J., Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study (2012) Leukemia, 26 (1), pp. 149-157; Genadieva-Stavric, S., Cavallo, F., Palumbo, A., New approaches to management of multiple myeloma (2014) Curr Treat Options Oncol, 15 (2), pp. 157-170; Edler, M., Jakubowski, N., Linscheid, M., Quantitative determination of melphalan DNA adducts using HPLC - Inductively coupled mass spectrometry (2006) J Mass Spectrom, 41 (4), pp. 507-516; Dronkert, M.L., Kanaar, R., Repair of DNA interstrand cross-links (2001) Mutat Res, 486 (4), pp. 217-247; Episkopou, H., Kyrtopoulos, S.A., Sfikakis, P.P., Association between transcriptional activity, local chromatin structure, and the efficiencies of both subpathways of nucleotide excision repair of melphalan adducts (2009) Cancer Res, 69 (10), pp. 4424-4433; Thompson, L.H., Hinz, J.M., Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: Mechanistic insights (2009) Mutat Res, 668 (1-2), pp. 54-72; Deans, A.J., West, S.C., DNA interstrand crosslink repair and cancer (2011) Nat Rev Cancer, 11 (7), pp. 467-480; Hanlon Newell, A.E., Hemphill, A., Akkari, Y.M., Hejna, J., Moses, R.E., Olson, S.B., Loss of homologous recombination or non-homologous end-joining leads to radial formation following DNA interstrand crosslink damage (2008) Cytogenet Genome Res, 121 (3-4), pp. 174-180; Gorrini, C., Harris, I.S., Mak, T.W., Modulation of oxidative stress as an anticancer strategy (2013) Nat Rev Drug Discov, 12 (12), pp. 931-947; Simonelli, V., Narciso, L., Dogliotti, E., Fortini, P., Base excision repair intermediates are mutagenic in mammalian cells (2005) Nucleic Acids Res, 33 (14), pp. 4404-4411; Bee, L., Fabris, S., Cherubini, R., Mognato, M., Celotti, L., The efficiency of homologous recombination and non-homologous end joining systems in repairing double-strand breaks during cell cycle progression (2013) PLoS One, 8 (7); Chernikova, S.B., Game, J.C., Brown, J.M., Inhibiting homologous recombination for cancer therapy (2012) Cancer Biol Ther, 13 (2), pp. 61-68; Kuo, L.J., Yang, L.X., Gamma-H2AX - A novel biomarker for DNA double-strand breaks (2008) In Vivo, 22 (3), pp. 305-309; Clingen, P.H., Wu, J.Y., Miller, J., Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy (2008) Biochem Pharmacol, 76 (1), pp. 19-27; Stefanou, D.T., Bamias, A., Episkopou, H., Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer (2015) PLoS One, 10 (2); Souliotis, V.L., Sfikakis, P.P., Increased DNA doublestrand breaks and enhanced apoptosis in patients with lupus nephritis (2015) Lupus, 24 (8), pp. 804-815; Plummer, R., Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target (2010) Clin Cancer Res, 16 (18), pp. 4527-4531; Lord, C.J., Ashworth, A., The DNA damage response and cancer therapy (2012) Nature, 481 (7381), pp. 287-294; Smith, J., Tho, L.M., Xu, N., Gillespie, D.A., The ATMChk2 and ATR-Chk1 pathways in DNA damage signaling and cancer (2010) Adv Cancer Res, 108, pp. 73-112; Pei, X.-Y., Dai, Y., Youssefian, L.E., Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2 (2011) Blood, 118 (19), pp. 5189-5200; Sousa, M.M., Zub, K.A., Aas, P.A., An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells (2013) PLoS One, 8 (2); Deriano, L., Guipaud, O., Merle-Béral, H., Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway (2005) Blood, 105 (12), pp. 4776-4783; Willmore, E., De Caux, S., Sunter, N.J., A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia (2004) Blood, 103 (12), pp. 4659-4665; Greipp, P.R., San Miguel, J., Durie, B.G., International staging system for multiple myeloma (2005) J Clin Oncol, 23 (15), pp. 3412-3420; Durie, B.G., Harousseau, J.L., Miguel, J.S., International uniform response criteria for multiple myeloma (2006) Leukemia, 20 (9), pp. 1467-1473; Stefanou, D.T., Episkopou, H., Kyrtopoulos, S.A., Development and validation of a PCR-based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs (2012) Br J Clin Pharmacol, 74 (5), pp. 842-853; Souliotis, V.L., Dimopoulos, M.A., Episkopou, H.G., Kyrtopoulos, S.A., Sfikakis, P.P., Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure (2006) DNA Repair (Amst), 5 (8), pp. 972-985; Episkopou, H., Kyrtopoulos, S.A., Sfikakis, P.P., Dimopoulos, M.A., Souliotis, V.L., The repair of melphalan-induced DNA adducts in the transcribed strand of active genes is subject to a strong polarity effect (2011) Mutat Res, 714 (1-2), pp. 78-87; Gkotzamanidou, M., Terpos, E., Bamia, C., Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis (2014) Leukemia, 28 (5), pp. 1113-1121; Avramis, I.A., Christodoulopoulos, G., Suzuki, A., In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines (2002) Cancer Chemother Pharmacol, 50 (6), pp. 479-489; Bellamy, W.T., Dalton, W.S., Gleason, M.C., Grogan, T.M., Trent, J.M., Development and characterization of a melphalan-resistant human multiple myeloma cell line (1991) Cancer Res, 51 (3), pp. 995-1002; Stronach, E.A., Chen, M., Maginn, E.N., DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance (2011) Neoplasia, 13 (11), pp. 1069-1080; Amrein, L., Loignon, M., Goulet, A.C., Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA doublestrand break repair via inhibition of DNAdependent protein kinase (2007) J Pharmacol Exp Ther, 321 (3), pp. 848-855; Srivastava, M., Nambiar, M., Sharma, S., An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression (2012) Cell, 151 (7), pp. 1474-1487; Budke, B., Logan, H.L., Kalin, J.H., RI-1: A chemical inhibitor of RAD51 that disrupts homologous recombination in human cells (2012) Nucleic Acids Res, 40 (15), pp. 7347-7357; Gkotzamanidou, M., Sfikakis, P.P., Kyrtopoulos, S.A., Bamia, C., Dimopoulos, M.A., Souliotis, V.L., Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma (2014) Br J Cancer, 111 (7), pp. 1293-1304; Souliotis, V.L., Dimopoulos, M.A., Sfikakis, P.P., Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards (2003) Clin Cancer Res, 9 (12), pp. 4465-4474; Li, Y.H., Wang, X., Pan, Y., Lee, D.H., Chowdhury, D., Kimmelman, A.C., Inhibition of non-homologous end joining repair impairs pancreatic cancer growth and enhances radiation response (2012) PLoS One, 7 (6); Spanswick, V.J., Craddock, C., Sekhar, M., Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma (2002) Blood, 100 (1), pp. 224-229; Dimopoulos, M.A., Souliotis, V.L., Anagnostopoulos, A., Papadimitriou, C., Sfikakis, P.P., Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stemcell transplantation is individualized and may predict clinical outcome (2005) J Clin Oncol, 23 (19), pp. 4381-4389; Dimopoulos, M.A., Souliotis, V.L., Anagnostopoulos, A., Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma (2007) Haematologica, 92 (11), pp. 1505-1512; Gong, F., Kwon, Y., Smerdon, M.J., Nucleotide excision repair in chromatin and the right of entry (2005) DNA Repair (Amst), 4 (8), pp. 884-896; Lehmann, A.R., Niimi, A., Ogi, T., Translesion synthesis: Y-family polymerases and the polymerase switch (2007) DNA Repair (Amst), 6 (7), pp. 891-899; Hanada, K., Budzowska, M., Modesti, M., The structure-specific endonuclease Mus81-Eme1 promotes conversion of interstrand DNA crosslinks into double-strands breaks (2006) EMBO J, 25 (20), pp. 4921-4932; Buis, J., Wu, Y., Deng, Y., Mre11 nuclease activity has essential roles in DNA repair and genomic stability distinct from ATM activation (2008) Cell, 135 (1), pp. 85-96; Helleday, T., Lo, J., Van Gent, D.C., Engelward, B.P., DNA double-strand break repair: From mechanistic understanding to cancer treatment (2007) DNA Repair (Amst), 6 (7), pp. 923-935